mdr1甲基化与宫颈癌新辅助化疗疗效相关性研究

目的：研究宫颈癌肿瘤细胞多药耐药基因1（mdr1）甲基化与宫颈癌新辅助化疗疗效相关性，探索适用于预测临床化疗多药耐药性的敏感指标。方法：采用MassARRYEpiTYPERDNA甲基化分析技术定量分析宫颈鳞癌（n=40）新辅助化疗前后、正常对照组（n=30）中的mdr1基因启动子区15个CpG位点的甲基化状态。结果：新辅助化疗敏感组（n=31）CpG2、3、4位点甲基化率高于行新辅助化疗耐药组（n=9），差异有统计学意义（P〈0．05）；与新辅助化疗前组相比，化疗后组CpG_7、CpG_8、CpG_12、13、CpG_18、CpG_19、20、CpG_23、CpG_24位点甲基化率减低，差异有统计学意义（p〈0．05）；与正常组织（n=30）相比，宫颈癌（n=80）CpG_2、3、4、CpG_5、CpG6、CpG_7、CpG_8、CpG_9、10、CpG-12、13、CpG_18、CpQ_19、20、CpG_22、CpG_23、CpG_24位点甲基化率较低，差异有统计学意义（p〈0．05）。结论：宫颈癌mdr1基因甲基化水平高低与宫颈癌NACT疗效有一定相关性。

Associoation of mdrl gene methylation status with NACT effects of cervical cancer

Objective： To research the correlation between methylation status of cervical cancer tumor cell multidrug resistace gene 1 with the curative effect of cervical cancer, to ivestigate some sensitive index can predict the clinical effects of multidrug resistenee. Method： MassARRY EpiTYPER DNA methylation analyzing technique was used to detect the 15 CPG silos status ofmdrl gene promoter region which in groups before and aider NACT of cervical cancer and nomal group. Results： In comparison with NACT sensitive group （n=31）, the methylation status in drug resistence group （n = 9） was lower （p 〈0.05 ） on CpG_2, 3, 4 site;comparing with the untreated patients （n =40）, the methylation status in drug resistence group were lower in the patients with NACT （ n = 14）on CpG_7, CpG_8, CpG_12, 13, CpG_18, CpG_19, 20, CpG_23, CpG_24 sites （P〈0. 05）;the methylation status in cervical cancer group （n=80）were lower than in the nomal group （n=30） on CpG_2, 3, 4, CpG_5, CpG_6, CpG_7, CpG_8, CpG9, 10, CpG_12, 13, CpG 18, CpG_19, 20, CpG_22, CpG_23, CpG_24 sites （P〈0. 05）. Conelutiun： There is relative correlation between the methylation status of multidrug resistance gene 1 in cervical cancer tumor cell with the curative effect of cervical cancer.